Vertex Pharmaceuticals (VX1) Stock Statistics & Valuation Metrics

Vertex Pharmaceuticals has a market cap or net worth of $92.97B. The enterprise value is €96.43B.

Vertex Pharmaceuticals has 253,718,830 shares outstanding. The number of shares has decreased by -2.65% in one year.

Vertex Pharmaceuticals’s return on equity (ROE) is -0.03 and return on invested capital (ROIC) is 2.62%.

The current PE Ratio of Vertex Pharmaceuticals is 28.8. Vertex Pharmaceuticals’s PEG ratio is 1.69.

In the last 12 months, Vertex Pharmaceuticals had revenue of 11.02B and earned -535.60M in profits. Earnings per share was -2.08.

In the last 12 months, operating cash flow was 3.72B and capital expenditures -380.80M, giving a free cash flow of 3.34B billion.

Vertex Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Vertex Pharmaceuticals upcoming earnings date is Feb 4, 2026, After Close (Confirmed).

Vertex Pharmaceuticals as a current ratio of 2.69, with Debt / Equity ratio of 7.38%

In the past 12 months, Vertex Pharmaceuticals has paid 784.10M in taxes.

Vertex Pharmaceuticals EV to EBITDA ratio is 207.43, with an EV/FCF ratio of -127.64.

Vertex Pharmaceuticals has $6.29B in cash and marketable securities with $1.83B in debt, giving a net cash position of $4.45B billion.

Gross margin is 86.28%, with operating margin of -2.11%, and net profit margin of -4.86%.

The average price target for Vertex Pharmaceuticals is $423.58, which is 11.43% higher than the current price. The consensus rating is Moderate Buy